Cardiovascular side-effects and insulin secretion after intravenous administration of radiolabeled Exendin-4 in pigs

Nucl Med Biol. 2016 Jul;43(7):397-402. doi: 10.1016/j.nucmedbio.2016.04.002. Epub 2016 Apr 16.

Abstract

Introduction: Radiolabeled Exendin-4, a synthetic glucagon-like peptide-1 (GLP-1) analog, is used as a tracer for diagnostic purposes of β-cells and in experimental animal research. Exendin-4 can be radiolabeled with (68)Ga, (111)In or (99m)Tc and used for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging to diagnose insulinomas, visualization of pancreatic β-cell mass and transplanted Islets of Langerhans. In humans, Exendin-4 is widely used as a therapeutic agent for treatment of type 2 diabetes (T2D). The compound, which is administered subcutaneously (SC) may cause nausea, vomiting and a minor increase in the heart rate (HR). However, possible side-effects on cardiovascular functions after intravenous (IV) administration have not been reported. This study describes the Exendin-4 dose at which cardiovascular side-effects occur in pigs and cynomolgus monkeys. The IV effect of the tracer on insulin secretion is also investigated in pigs.

Methods: Seven clinically healthy littermate pigs (40days old) were used; three of them were made diabetic by streptozotocin (STZ). All pigs underwent PET imaging under general anesthesia to examine the glucagon-like peptide-1 receptor (GLP-1R) in β-cells with radiolabeled Exendin-4. A baseline tracer dose IV [(68)Ga]Exendin-4 (0.025±0.010μg/kg) followed by a competition dose IV [(68)Ga]Exendin-4 (3.98±1.33μg/kg) 60min later were administered. Blood samples were taken and analyzed for insulin secretion by using ELISA. Cardiovascular and respiratory variables were monitored throughout the experiment.

Results: Immediately after administration of the high dose [(68)Ga]Exendin-4 the HR rose from 122±14 to 227±40bpm (p<0.01) and from 100±5 to 181±13bpm (p<0.01) in healthy non-diabetic and diabetes-induced pigs, respectively. The tachycardia was observed for >2h and one healthy non-diabetic pig suffered cardiac arrest 3h after the IV [(68)Ga]Exendin-4. Arrhythmia was detected by listening to the heart with a stethoscope up to 4days after the [(68)Ga]Exendin-4 injection. In all animals, no effect on the cardiovascular system was registered after the low dose of IV [(68)Ga]Exendin-4. Insulin secretion increased (p<0.05) when IV [(68)Ga]Exendin-4 was given in dosages ≥0.14μg/kg.

Conclusions: Intravenous administration of ≥2.8μg/kg [(68)Ga]Exendin-4 resulted in severe tachycardia and arrhythmias in healthy non-diabetic and diabetes-induced pigs, and the insulin secretion was stimulated in healthy non-diabetic animals when ≥0.14μg/kg [(68)Ga]Exendin-4 was given.

Keywords: Adverse-effects; Arrhythmias; Exenatide; Imaging; Monkeys; PET; Swine; Tachycardia.

MeSH terms

  • Administration, Intravenous
  • Animals
  • Arterial Pressure / drug effects
  • Blood Glucose / metabolism
  • Cardiovascular System / diagnostic imaging
  • Cardiovascular System / drug effects*
  • Dose-Response Relationship, Drug
  • Exenatide
  • Female
  • Heart Rate / drug effects
  • Insulin / blood
  • Insulin / metabolism*
  • Insulin Secretion
  • Male
  • Peptides / administration & dosage*
  • Peptides / adverse effects*
  • Positron-Emission Tomography
  • Swine
  • Venoms / administration & dosage*
  • Venoms / adverse effects*

Substances

  • Blood Glucose
  • Insulin
  • Peptides
  • Venoms
  • Exenatide